Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients

Current Medical Research and Opinion

Volumn 21, Issue 1, 2005, Pages 37-46

  Leonetti, Gastone ^a   Emeriau, Jean Paul ^b   Knauf, Heinrich ^c   Pujadas, Juan Ocon ^d   Calvo Gomez, Carlos ^e   Abate, Giuseppe ^f  

^a Ospedale San Luca   (Italy)

^b Ctr Geriatrie Ctr Hosp Univ B   (France)

^c ST BERNWARD KRANKENHAUS   (Germany)

^d FUNDACIÓ PUIGVERT   (Spain)

^e HOSPITAL GENERAL DE GALICIA   (Spain)

^f UNIVERSITY OF CHIETI   (Italy)

Author keywords

Acceptability; Diuretics; Efficacy; Elderly patients; Hypertension; Indapamide SR; Isolated systolic hypertension; Long term treatment

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE;

AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTION SICKNESS; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; SUPINE POSITION; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; AMLODIPINE; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDAPAMIDE; MALE; TREATMENT OUTCOME;

EID: 14744271688     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X15228     Document Type: Article

References (37)

1. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-12
2. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug-treatment in older persons with isolated systolic hypertension. J Am Med Assoc 1991;265:3255-64
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38
4. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension. Lancet 1991;338:1281-5
5. Anon. National High Blood Pressure Education Program. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46
6. World Health Organization, Guidelines Subcommittee. International Society of Hypertension guidelines for the management of hypertension. J Hypertens 2003;21:1983-92
7. Anon. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
8. Leonetti G, Rappelli A, Salvetti A, Scapellato L. Long-term effects of indapamide: final results of a 2-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990;65:67H-71H
9. Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984;28:189-235 [updated June 1988]
10. Senior R, Imbs J-L, Bory M, et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol 1993;22:106-10
11. Carey PA, Sheridan DJ, de Cordoüe A, Guez D. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996;77:17B-19B
12. Leonetti G, Rappelli A, Salvetti A, Scapellato L. Tolerability and well-being with indapamide in the treatment of mild-moderate hypertension. Am J Med 1988;84(Suppl 1B):59-64
13. Ames RP. A comparison of blood lipid and blood pressure responses during treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996;77:12B-16B
14. Mallion J-M, Asmar R, Boutelant S, Guez D. Twenty-four hour antihypertensive efficacy of indapamide 1.5-mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998;32:673-8
15. Ambrosioni E, Safar M, Degaute J-P, et al., on behalf of the European Study Group. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomized double-blind controlled studies. J Hypertens 1998;16:1677-84
16. Gosse P, Sheridan DJ, Zannad F, et al., on behalf of the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapfil 20 mg: The LIVE study. J. Hypertens 2000;18:1465-75
17. Marre M, Garcia Puig, Kokot F, et al., on behalf of the Coordinators Study Group. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study. J Hypertens 2004;22:1613-22
18. Weidmann P. Metabolic profile of indapamide sustained-released in patients with hypertension. Data from three randomised double-blind studies. Drug Safety 2000;24(15):1155-65
19. Emeriau JP, Knauf H, Pujadas JO, et al., European Study Investigators. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001;19:343-50
20. Emeriau JP, Decamps A, Manciet G, Dupuy-Braud E, Galley P. Hypertension in the elderly. Am J Med 1988;84:92-7
21. Curb JD, Borhani NO, Entwisle G, et al. [original contributions]. Isolated systolic hypertension in 14 communities. Am J Epidemiol 1985;121:362-70
22. Curb JD, Borhani NO, Entwisle G, et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. J Am Med Assoc 1981;245:1225-9
23. Staessen JA. The epidemiology of isolated systolic hypertension in the elderly. Medicographia 1998;20:8-14
24. Whelton PK. Epidemiology of hypertension. Lancet 1994;344:101-6
25. Wolf PA, D'Agostino RB, Belanger AL, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 1991;22:312-8
26. Kannel WB, Dannenberg AL, Abbot RD. Unrecognized myocardial infarction and hypertension: the Framingham study. Am Heart J 1995;109:581-5
27. Bulpitt CJ, Fletcher AE. Prognostic significance of blood pressure in the very old. Implications for the treatment decision. Drugs Aging 1994;5:184-91
28. Izzo Jr JL, Levy D, Black HR. Clinical advisory statement: importance of systolic blood pressure in older Americans. Hypertension 2000;35:1021-4
29. Jackson G, Pierscianowski TA, Mahon W, Condon J. Inappropriate antihypertensive therapy in the elderly. Lancet 1976;2:17-8
30. Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992;10:1103-9
31. Ekbom T, Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester P-O. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report of the STOP-Hypertension study. J Hypertens 1992;10:1525-30
32. Gueyffier F, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials [INDANA Group]. Lancet 1999;353:793-6
33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. J Am Med Assoc 2002;288:2981-97
34. Anon. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure - the JNC 7 Report. J Am Med Assoc 2003;289(19):2560-72
35. Mac Mahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. J Clin Exp Hypertens 1993;15:967-78
36. World Health Organization - International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. J Hypertens 1998;16:127-37
37. Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the Very Elderly Trial (HYVET). Protocol for the main trial. Drugs Aging 2001;18(3):151-64